A variation to the clinical staging of AD was proposed by the National Institute on Aging – Alzheimer’s Association (NIA-AA) working group (2018) using six clinical stages for persons who are amyloid positive.
The NIA-AA Research Framework describes AD as a biological construct that can be identified in living persons via Aβ and tau biomarkers.
In the NIA-AA framework, biomarkers are used to identify the presence of AD, with clinical stages used to indicate disease severity.
Read more about New clinical staging of Alzheimer’s disease
Related content
Professor Dr. Matthew Kiernan discusses the limitations of current trial models.
Professor Dr. Matthew Kiernan discusses the limitations of current trial models.
Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021